Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1605 - Phase 2 study of the combination of lisocabtagene maraleucel, nivolumab, and ibrutinib in Richter’s transformation - NCT05672173

    Primary Author / Presenter(s)

  • Tanya Siddiqi, MD

    Professor
    City of Hope Orange County
    Irvine, California, United States

    • Co-Author(s)

  • JB

    John Baird, MD

    City of Hope National Medical Center
    Duarte, California, United States

  • AB

    Alexander Boardman, MD

    Memorial Sloan Kettering Cancer Center
    New York, New York, United States

  • MC

    Mary Clark, Staff Scientist

    City of Hope National Medical Center
    Duarte, New York, United States

  • LC

    Lu Chen, PhD

    City of Hope National Medical Center
    Duarte, California, United States

    • Co-Author(s)

  • VS

    Vivian Song, RN

    City of Hope National Medical Center
    Duarte, California, United States

    • Co-Author(s)

  • GS

    Geoffrey Shouse, DO

    City of Hope National Medical Center
    Duarte, California, United States

  • AK

    Avyakta Kallam, MD

    City of Hope National Medical Center
    Duarte, California, United States

  • SR

    Steven T. Rosen, MD

    Provost & Chief Scientific Officer
    Toni Stephenson Lymphoma Center, Beckman Research Institute,City of Hope
    Duarte, California, United States

  • Alexey V. Danilov, MD, PhD

    Professor
    Department of Hematology and Transplantation, City of Hope National Medical Center
    Duarte, California, United States

  • Lili Wang, MD, PhD

    Associate Professor, Department of Systems Biology
    Department of Systems Biology, Beckman Research Institute, City of Hope
    Monrovia, California, United States